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Abstract
We demonstrate in the current work that small cationic antimicrobial β2,2-amino acid deriva-
tives (Mw < 500 Da) are highly potent against Chlamydia pneumoniae at clinical relevant
concentrations (< 5 μM, i.e. < 3.4 μg/mL). C. pneumoniae is an atypical respiratory patho-
gen associated with frequent treatment failures and persistent infections. This gram-nega-
tive bacterium has a biphasic life cycle as infectious elementary bodies and proliferating
reticulate bodies, and efficient treatment is challenging because of its long and obligate
intracellular replication cycle within specialized inclusion vacuoles. Chlamydicidal effect of
the β2,2-amino acid derivatives in infected human epithelial cells was confirmed by transmis-
sion electron microscopy. Images of infected host cells treated with our lead derivative A2
revealed affected chlamydial inclusion vacuoles 24 hours post infection. Only remnants of
elementary and reticulate bodies were detected at later time points. Neither the EM studies
nor resazurin-based cell viability assays showed toxic effects on uninfected host cells or
cell organelles after A2 treatment. Besides the effects on early intracellular inclusion vacu-
oles, the ability of these β2,2-amino acid derivatives to suppress Chlamydia pneumoniae
infectivity upon treatment of elementary bodies suggested also a direct interaction with bac-
terial membranes. Synthetic β2,2-amino acid derivatives that target C. pneumoniae repre-
sent promising lead molecules for development of antimicrobial agents against this hard-to-
treat intracellular pathogen.
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Introduction
Chlamydia pneumoniae (alternatively called Chlamydophila pneumoniae) is an air-borne respi-
ratory tract pathogen typically causing a long-lasting dry cough with gradual onset [1, 2].
While approximately 70% of acute C. pneumoniae respiratory tract infections are mild or
asymptomatic, a significant fraction of them cause more severe respiratory tract illnesses such
as sinusitis, bronchitis and upper airway illnesses [3]. Furthermore, estimated 5–10% of com-
munity-acquired pneumonia cases are caused by C. pneumoniae, and especially the elderly
patients often suffer from a severe illness upon encountering this pathogen [4].
In vitro susceptibility studies have shown that C. pneumoniae is sensitive to macrolides, tet-
racyclines and quinolones, but complete eradication of the infection is challenging. C. pneumo-
niae is resistant to sulfa drugs and trimethoprim, and treatment with penicillins can trigger the
formation of a persistent state [5]. Treatment of C. pneumoniae infections is associated with
relapsing symptoms and treatment failures even when the first-choice antibiotics are used. Up
to 30% of patients with C. pneumoniae-caused community acquired pneumonia harbor the
bacterium in a cultivable form even after the treatment and symptoms have ceased [5, 6].
Upon treatment failures and non-treated infections, the bacterium may convert to a chronic
form characterized by morphological, transcriptional and metabolic changes different from the
acute infectious phase. This persistent form of infection is ultimately refractory to even pro-
longed treatment with antibiotic agents [7, 8]. Despite its non-replicative nature, the persistent
C. pneumoniae infection manipulates the host cell metabolism and signaling pathways, and
activation of several proinflammatory and proliferative pathways are associated with the infec-
tion [9].
C. pneumoniae represents an atypical respiratory tract pathogen by being a gram-negative
bacterium with an obligate intracellular replication cycle. Characteristic for the life cycle of C.
pneumoniae are successive conversions between the extracellular, non-replicative but infec-
tious elementary bodies (EBs), and the intracellular replicating reticulate bodies (RBs). Bacteria
in the genus Chlamydia resemble other gram-negative bacteria as they have an outer mem-
brane rich in negatively charged lipooligosaccharides (LOS) [10]. Recently, it has also been
shown that Chlamydia spp. possess a peptidoglycan cell wall [11]. Cysteine-rich proteins are
abundant in the proximity of the outer membrane of the Chlamydia cell envelope. These form
extraordinary intra- and intermolecular disulfide cross-linkages involving proteins such as the
major outer membrane protein (MOMP) and other periplasmic cysteine-rich proteins, which
are suspected to play a crucial role in the structural rigidity and osmotic stability of the EBs
form [12, 13]. Reduction of the disulfide bonds as well as opening of the supramolecular pro-
tein complexes occurs upon differentiation of the EBs to RBs shortly after entering the host cell
and contributes to the fragile and osmolabile nature of the intracellular RB form [14]. Chla-
mydia spp. have developed means to support their intracellular survival. The formation of an
inclusion vacuole, which is detached from the host cell’s endocytic vesicular system, is essential
upon the bacterium’s entry into the host cell [15]. The inclusion membrane provides a protec-
tive niche by being an additional permeability barrier against cellular defense mechanisms and
antimicrobial agents, and offers a surface for anchoring bacterial and host cell proteins favor-
able for the infection.
The negatively charged lipooligosaccharides embedded in the outer membrane of C. pneu-
moniae display a possible and favorable target structure for treatment with cationic antimicro-
bial peptides (AMPs). AMPs are a structurally diverse class of naturally existing anti-infective
agents forming an essential component of the innate immune system of all multicellular organ-
isms [16]. The antimicrobial activity of the majority of these peptides is tightly linked to their
ability to electrostatically interact, insert and finally disrupt bacterial membranes. Selective
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interaction of AMPs with microbial membranes is explained by a higher negatively charged
outer surface and lack of cholesterol compared to eukaryotic cell membranes. Similar observa-
tions have been made on cancer cells and several AMPs are regarded as promising cancer ther-
apeutics, especially for treatment of resistant tumors [17, 18]. In order to have antimicrobial or
anticancer properties, AMPs require in general a certain content and distribution of cationic
and lipophilic residues enabling formation of amphipathic peptide conformations, rather than
the presence of specific amino acid sequences [19].
The use of AMPs as potential pharmaceutical agents has been investigated during the last
three decades. However, an inherent obstacle in using peptides as therapeutic agents is related
to their unfavorable pharmacokinetic properties like compromised oral bioavailability, and low
metabolic and proteolytic stability. Thus, most AMPs in clinical trials are developed as topical
formulations [20]. A strategy to overcome these obstacles is to prepare peptidomimetics, which
are molecules that maintain or improve essential peptide functionalities with respect to biologi-
cal activity. These molecules are less susceptible to enzymatic degradation and have otherwise
more favorable pharmacokinetic properties [21]. We have reported the synthesis of a series of
peptide mimicking β2,2-amino acid derivatives that resemble small AMPs and additionally ful-
fill the physicochemical criteria set for orally bioavailable drugs [22]. These derivatives show
activity against both gram-positive and gram-negative bacteria with minimum inhibitory con-
centration values between 4–8 μMwhile being basically nontoxic against human red blood
cells. Of importance to the present study is the observation that β2,2-amino acid derivatives are
able to permeate through artificial cell membranes by passive diffusion, and our hypothesis
thereby became that they also could target intracellular residing pathogenic bacteria such as C.
pneumoniae [22]. It has been reported that AMPs are able to effectively kill metabolically inac-
tive extracellular EBs of C. pneumoniae and C. trachomatis [23]. However, bactericidal effects
of AMPs on intracellular residing Chlamydia spp. is to our knowledge not reported.
In the current work, we demonstrate that derivatives A1 and A2, two out of our six studied
β2,2-amino acid derivatives (Fig 1), are highly potent and able to inhibit Chlamydia pneumo-
niae infectivity and interfere with C. pneumoniae inclusions in human epithelial HL cells at
concentrations below 5 μM (3.4 μg/mL). We hypothesize that the antichlamydial properties
are based on a dual mechanism of action of these derivatives affecting both the EBs and early
intracellular inclusions of C. pneumonia.
Materials and Methods
Derivatives A1—A6
The derivatives A1—A6 were synthesized according to previous publications and isolated as
di-trifluoroacetate salts [22, 24]. Purity was determined to> 95% with an analytical RP-HPLC
C18-column and UV detection at 214 nm and 254 nm.
Cells and bacteria
Human epithelial HL cells [25] were grown in a RPMI1640 medium supplemented with 7.5%
fetal bovine serum (FBS), 2 mM L-glutamine and 20 μg/ml gentamicin sulfate. A clinical C.
pneumoniae isolate Kajaani 7 (K7), originally isolated from a young Finnish man suffering
from pneumonia [26] was obtained from Professor Pekka Saikku (Department of Medicinal
Microbiology, Institute of Diagnostics, University of Oulu, Finland) and a cardiovascular C.
pneumoniae isolate CV-6 was obtained from Professor Matthias Maass (Paracelsus Medical
University, Salzburg, Austria). The reference strains CWL-029 (VR-1310) and AR-39 (ATCC
53592) were obtained from American Type Culture Collection (ATCC). All strains were
propagated in HL cells as previously described [27]. The K7 strain was used in all studies
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whereas CV-6 and the ATCC reference strains were used to confirm our initial compound
screening data.
Infections
For all experiments applying immunofluorescence, HL cells were seeded in 24-well plates with
coverslips at density of 4 x 105 cells/well and incubated overnight before infection. The cells
were inoculated with C. pneumoniae at multiplicity of infection (MOI) 0.2 in the cell growth
media supplemented with 1 μg/ml cycloheximide to enhance chlamydial growth [28]. The
inoculated cultures were centrifuged at 550 g at 4°C for 1 h and incubated at 37°C for 1 h. Inoc-
ula were removed, fresh medium was added into wells and the plates were incubated for 70 h.
Afterwards the cultures were fixed with methanol and the coverslips were stained with Path-
finder Chlamydia cell culture confirmation system (Bio-Rad) based on a genus-specific anti-LPS
antibody to visualize the host cells and chlamydial inclusions. Detailed protocols for the infec-
tion and staining can be found in [29]. Unless otherwise stated in the text, the derivatives were
added into the culture medium at 2 hours post infection (hpi), i.e., at the time when inocula
were removed. Rifampicin (Fluka) at a concentration of 12 nM and azithromycin (Sigma) at a
concentration 20 nM were used as a positive control in the infections, consistently yielding 95–
98% inhibition in C. pneumoniae inclusion counts. DMSO concentration was adjusted to 0.1%
in all experiments.
Delayed administration assay
HL cells were infected as described above and treated with derivatives at concentrations of
3 μM in order to cause inhibition of infection above 50%. The treatment of the infected cells
Fig 1. Structures of the investigated β2,2-amino acid derivatives A1—A6. All derivatives were isolated as di-trifluoroacetate salts.
doi:10.1371/journal.pone.0157306.g001
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was delayed by 4, 10 and 22 h and inclusions counts were subsequently performed as described
above.
Infectious progeny assay
To measure the effects of the β2,2-amino acid derivatives on production of new infectious prog-
eny by C. pneumoniae, HL cells were infected with C. pneumoniae as described above in the
presence of the derivatives (at a concentration of 5 μM). At 72 hpi, medium was removed from
the wells and 200 μl fresh medium was added. The cells were scraped off and then further lysed
by vortexing with glass beads, and the lysates were used to infect fresh HL cell monolayers.
Inclusion counts in the second passage of infection were determined with immunofluorescent
staining as described above, and control wells fixed and stained after the first infectious cycle
were used as internal controls.
Elementary body infectivity assay
C. pneumoniae EBs were suspended into the HL cell growth medium supplemented with cyclo-
heximide at 400 000 inclusion forming units (IFU)/ml and exposed to 5 μM of the derivatives
A1—A6 for 1 h at 4°C. Immediately afterwards, aliquots of the EBs suspensions were used to
infect HL cell monolayers as described above (MOI 0.2), resulting in typically 40–60 inclusions
per eye field in nontreated control infections.
Transmission electron microscopy
HL cells were seeded in 6-well plates at 2 x 106 cells per well and cultured overnight. The cell
monolayers were infected with C. pneumoniae (MOI 1) and treated with 2.5 μM of derivative
A2 by adding it to the culture medium at 2 hpi based on findings in the dose-response assay.
Untreated and uninfected HL control cells were incubated concurrently. The cells were pre-
fixed at 24, 48 and 72 hpi with Karnovsky's fixative at 4°C, overnight. The samples were further
processed for TEM as described in [30].
Cell viability assays
HL cells were seeded into 96-well plates at density 6 x 105 cells per well and incubated over-
night before starting the exposure. The β2,2-amino acid derivatives were added at concentra-
tions of 5 μM either in the presence or absence of 1 μg/ml cycloheximide in a final volume of
200 μl and the plates were incubated for 72 h. The resazurin assay was performed as described
in Karlsson et al. [31].
Data analysis
All experiments were carried out as four replicates in minimum and the inclusion counts were
determined as mean ± SEM of 4 eye fields per coverslip. For statistical analysis GraphPad
Prism software v. 5.0 and Student’s t-test (p< 0.05) were applied.
Results
Inhibition of C. pneumoniae growth by β2,2-amino acid derivatives
Six β2,2-amino acid derivatives, comprising three different lipophilic side-chains and two differ-
ent cationic C-termini (Fig 1) were assayed in a protocol in which human HL epithelial cell
monolayers were infected with C. pneumoniae strain K7. At a concentration of 5 μM (A1,
3.4 μg/mL; A2, 3.2 μg/mL) the two derivatives, A1 and A2, yielded 95.6% and 100% reduction
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in inclusion counts with no substantial effect on host HL cell viability (Fig 2A). The derivatives
A3 and A6 caused full inhibition of C. pneumoniae infectivity, however, we observed that host
HL cells started to detach from the coverslips. The cell viability assay confirmed the rather
cytotoxic properties of these two derivatives against HL cells and viability was determined to be
30.6% for A3 and 18.4% for A6. Derivative A4 showed 23.2% inhibition against C. pneumoniae
and no cytotoxic effects against HL-cells whereas A5 caused 89.8% inhibition against C. pneu-
moniae and a 35.6% reduction of HL cell viability. As shown by the data from dose-response
experiments, the anti-chlamydial effect of A1 and A2 was dose-dependent and IC50 values of
2 μM (A1, 1.4 μg/mL; A2, 1.3 μg/mL) were obtained for both compounds (Fig 2B). The antic-
hlamydial efficacy of A1 and A2 was additionally confirmed using two ATCC reference strains,
AR-39 and CWL-029, and a cardiovascular C. pneumoniae isolate CV-6. These strains showed
similar susceptibility to treatment with 5 μM of these derivatives as observed for the K7 strain
(data not shown).
Impact of administration time on C. pneumoniae inhibition
To further analyze the inhibitory properties of the two most promising β2,2-amino acid deriva-
tives on C. pneumoniae growth, A1 and A2 were investigated in a delayed administration
experiment. The addition of the derivatives into the culture medium of infected cell monolay-
ers was postponed within the C. pneumoniae 72 h replication cycle. As indicated by the col-
umns presented in Fig 3A, adding 3 μM of A1 into the culture medium according to the
standard procedure (administration at 2 h, i.e. at the time of inocula removal) resulted in
approximately 70% inhibition of inclusion vacuole counts, as expected. When A1 was added at
6 hpi or later, the inhibitory effect was significantly decreased to approximately 10–20% reduc-
tion in inclusion vacuole counts. Derivative A2 followed the same pattern with approximately
80% reduction of inclusion vacuole counts when added at 2 hpi, and showed only inhibiting
effects on inclusion vacuole counts in a range between 20–30% when added at any later time
points. The size of the remaining inclusion vacuoles did not differ from those in untreated con-
trol infections at any time point. Thus, the most pronounced effect caused by A1 and A2 on C.
pneumoniae growth was exerted during the early stages of the infectious cycle.
Impact on infectious progeny production
The ability of A1 and A2 to suppress the C. pneumoniae production of new infectious progeny
was studied to gain more insight into the anti-chlamydial effects of these two derivatives. The
results presented in Fig 3B show that inclusion vacuole counts detected in the second passage
of infection were significantly lower in A1 and A2 treated infections than the inclusion vacuole
counts of an untreated control infection. Consistent with the data obtained from the adminis-
tration time experiments, neither A1 nor A2 suppressed C. pneumoniae infectious progeny
production when they were administered into infected cell cultures at 6 hpi or later (data not
shown).
Effects on C. pneumoniae elementary bodies
A hallmark of AMPs and AMP derived compounds is their ability to act on metabolically qui-
escent bacteria by a membrane disruptive mechanism of action. We studied the impact of the
β2,2-amino acid derivatives on the metabolically quiescent infectious EBs of C. pneumoniae
that are able to resist both harsh environmental factors and treatment with antibiotics [32].
Infectious EB suspensions were treated with each of the derivatives A1—A6 at 5 μM for 1 h
prior to inoculation on HL cell monolayers in order to gain insight into susceptibility of the EB
membranes to all derivatives. As shown in Fig 4, all six derivatives decreased C. pneumoniae
β2,2-Amino Acid Derivatives against C. pneumoniae
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Fig 2. Impact of β2,2-amino acid derivatives onC. pneumoniae inclusion counts and host cell viability. (A)
Screening of the β2,2-amino acid derivativesA1—A6 for anti-C. pneumoniae activity and cytotoxicity at
concentrations of 5 μM. (B) Dose-response relationship of A1 andA2 for decreasing C. pneumoniae inclusion
counts. (Results display the mean ± SEM).
doi:10.1371/journal.pone.0157306.g002
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Fig 3. Impact of delayed A1 and A2 administration and inhibition of infectious progeny production by the
derivatives. (A) Inhibition of C. pneumoniae infectivity after delayed administration of 3 μM of derivativesA1 and
A2. (B) Inhibition of infectious progeny production by A1 andA2 at a concentration of 5 μM. (Results display the
mean ± SEM; asterisk indicate significant difference, p < 0.05).
doi:10.1371/journal.pone.0157306.g003
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EB infectivity, with A3 and A6 being the most potent derivatives in this respect, causing 77%
and 90% inhibition. Treatment of EBs with A4 and A5 resulted in 20% and 66% reduction of
infectivity. The two derivatives A1 and A2, capable of suppressing C. pneumoniae inclusion
counts in the context of cellular infections (see above) caused up to 50% decrease in infectivity
upon EB pretreatment, indicating that these compounds, too, were able to target C. pneumo-
niae EB membranes. No HL cell detachment or morphological changes were observed during
these experiments, indicating that the fractions of compounds to which HL cells were exposed
in these conditions did not cause cytotoxic effects.
Transmission electron microscopy (TEM)
TEM was used to trace intracellular changes upon C. pneumoniae infection and treatment with
the lead derivative A2 (Fig 5). Treatment of HL cells with 2.5 μM of A2 over a time-span of 72
hpi did not result in remarkable changes in cell or organelle morphology compared with unin-
fected and untreated control cells (Fig 5Ia, 5lb, 5IIa and 5IIb). After infection with EBs and sub-
sequent incubation for 24 h, RBs were visible in untreated control cells (Fig 5IIIa and 5IIIb)
whereas affected inclusion vacuoles were visible in cells treated with A2 (Fig 5IVa and 5IVb).
By extending the incubation time to 48 h we observed an increased number of RBs per inclu-
sion vacuole and expansion of the latter (Fig 5Va and 5Vb). Treatment with A2 resulted in
smaller inclusions, which only contained fragments of RBs and EBs (Fig 5VIa and 5VIb). After
a 72 hpi course of the study, extended accumulations of RBs, redifferentiating RBs, and spheri-
cal EBs were visible in the untreated HL-cells (Fig 5VIIa and 5VIIb). Miniature bodies
Fig 4. Treatment of C. pneumoniae elementary bodies with derivatives A1—A6. EBs were incubated with
derivatives A1—A6 at concentrations of 5 μM for 1 h. Suppression of infectivity of the EBs was determined after
inoculation of HL cells and 72 h of incubation. (Results display the mean ± SEM).
doi:10.1371/journal.pone.0157306.g004
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Fig 5. Transmission electron microscopy images of HL-cells. Images of untreated HL cells (uninfected and infected
withC. pneumoniae) and HL cells treated with 2.5 μM ofA2 (uninfected and infected withC. pneumoniae) at different time
intervals (hpi: hours post infection) were acquired (see Materials andmethods for details). Scale bar in a series indicates
5 μm, whereas b series showsmagnified regions with scale bar representing 0.5 μm. In VIIb: Triangle = Reticulate body,
arrow = redifferentiating reticulate body, arrowhead = elementary body with miniature bodies.
doi:10.1371/journal.pone.0157306.g005
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characteristic for C. pneumoniae were also visible. In contrast, no RBs or EBs were present in
the A2 treated cells, but inclusion vacuoles containing remnants of RBs and EBs after C. pneu-
moniae infection were visible (Fig 5VIIIa and 5VIIIb).
Discussion
Despite some recent advances in diagnostics and basic biological studies, C. pneumoniae
remains a challenging target for pharmacological intervention as illustrated by the high ratio of
treatment failures with currently available antibiotics [6]. In contrast to most other respiratory
pathogens, no resistant mutants of C. pneumoniae have been isolated from clinical samples to
date. Even strains originating from patients with treatment failure do not show altered in vitro
susceptibility profiles to antibiotics. Furthermore, previous in vitro studies do not show
remarkable differences in antibiotic susceptibility between different C. pneumoniae reference
strains or clinical isolates [33–35]. These observations indicate that persistence, rather than
resistance, is responsible for the treatment challenges and emphasizes the need for novel types
of antichlamydial agents not relying on bacterial replication.
In our earlier studies, various β2,2-amino acid derivatives have been shown to be active
against multi-resistant bacteria and to be able to permeate through phospholipid membranes
[22]. Furthermore, we have reported that biofilms formed by Staphylococcus aureus and
Escherichia coli are susceptible to treatment with these β2,2-amino acid derivatives [36]. We
have also demonstrated that some have anticancer activity by either attacking mitochondria in
cancer cells or the cancer cell membrane and that this is related to differences in molecular
structure [30]. The antimicrobial and permeability properties of β2,2-amino acid derivatives
encouraged us to investigate if the intracellular pathogen C. pneumoniae is susceptible to these
AMP derived compounds. Therefore, infected human epithelial HL cells as well as C. pneumo-
niae EBs were used in the screening.
A direct interaction of β2,2-amino acid derivatives with negatively charged heparan-sulfate
and LOS containing bacterial membranes of EBs during the initial phase of infection can, to a
certain extent, explain the anti-chlamydial effect of the derivatives. A3 and A6 were the most
potent derivatives when applied to EBs prior to infection. Previous studies have shown that
these two derivatives display pronounced membranolytic properties compared to other related
β2,2-amino acid derivatives [24]. In contrast, A1 and A2 were non-toxic and both derivatives
decreased C. pneumoniae infectivity when the bacterial EBs were treated prior to infection.
Thus, interactions of A1 and A2 with C. pneumoniae EBs during the late attachment phase to
HL cells (~ 2 hpi, onset of incubation) appear plausible. As a consequence, cell entry and devel-
opment of infection was hampered.
Compared to other types of nonconventional anti-chlamydial compounds previously iden-
tified by us, such as flavonoids and betulin-derived compounds [27, 37, 38], the present β2,2-
amino acid derivatives show similar or higher potencies against C. pneumoniae. Of note, the
ability of flavonoles like quercetin, rhamnetin and morin to penetrate membranes seems cru-
cial for their anti-chlamydial properties [27]. We thus hypothesize that the anti-chlamydial
properties of A1 and A2 are also based on their ability to passively diffuse across the HL cell
phospholipid bilayer and a subsequently form electrostatic interactions with C. pneumoniae
bacterial and/or cellular inclusion membranes inside the infected HL-cells. We suspect that
negative charges are present on endocytic vesicles containing C. pneumoniae EBs as reported
for the inclusion vacuoles of a related pathogen Chlamydia trachomatis [39]. The negative
charges on the endocytic vesicle originate from the membrane lipid phosphatidylserine, which
is preferentially found on the inner leaflet of cell membranes. However, during endocytosis
topological inversion of the phospholipid bilayer occurs and phosphatidylserine is located on
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the endosome exterior, as illustrated in Fig 6. According to the proposed mechanisms of
actions for AMPs, the following event is interaction of the lipophilic side chains of the amphi-
pathic β2,2-amino acid derivatives with the inclusion vacuole membrane and, upon disintegra-
tion, elimination of this protective niche needed for C. pneumoniae replication. We further
hypothesize that the inclusion vacuole membrane and physiological processes connected to it
are more susceptible to derivate interaction than the inner leaflet of the cell membrane, which
is supported by our viability data.
The proposed mechanism of action is further supported by data acquired during the delayed
administration assay. Time experiments showed that postponing the administration of A1 or
A2 by only four hours (from 2 to 6 h) reduced drastically the anti-chlamydial effect (Fig 3A).
This indicated that these derivatives suppress C. pneumoniae growth by affecting the events
occurring in the early stages of the bacterial replication cycle. Similar observations have been
made for the 21 amino acid long cell penetrating peptide Pep-1 and the 69 residue long intra-
cellular expressed AMP CIT 1a [40, 41]. Both peptides were screened against C. trachomatis
and displayed their highest activity during the initial stages of infection. The hours following
the entry of Chlamydia into host cells are known to involve various remodeling processes of
Fig 6. Schematic drawing of HL cell infection byC. pneumoniae and potential intervention points of β2,2-amino acid derivatives. The cytosol is
surrounded by the inner (grey) and outer (black) leaflet of the cell membrane. The possible sites of inhibition of β2,2-amino acid derivatives during theC.
pneumoniae infection cycle are indicated by lightning symbols. Inhibition of infection progress is indicated by double strikethrough.
doi:10.1371/journal.pone.0157306.g006
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cellular membranes or organelles induced by the bacterium, as reviewed in Ronzone et al. [15].
The endocytic vesicle in which the EB is internalized is turned into an inclusion vacuole by
incorporation of a unique combination of bacterial and host cell membrane proteins. Exocytic
vesicles, multivesicular bodies and lipid droplets are trafficked into the inclusion vacuole to
provide lipids as energy source and building blocks for the bacterium. Moreover, Chlamydia
induced pathways prevent the fusion of the bacterium-endosomes with acidifying membrane
organelles, which provides a neutral pH in the inclusion vacuole and protects the bacterium
from degradation pathways [42].
Yeung et al. have reported that the related bacterium C. trachomatis actively manipulates
the composition of endosome membrane charge and phospholipid composition [39]. While
the abundance of phosphatidylserine in the outer leaflet of endosomal vesicles normally trig-
gers the fusion of the vesicle with lysosomes, C. trachomatis is able to reorganize the vesicle by
reducing the phosphatidylserine content and overall negative charge of the membrane’s outer
leaflet. These changes were found to occur by 6 h post infection, which coincides with the
observation from the delayed administration experiment of the current study (lack of inhibi-
tion when A1 or A2 were administered at 6 h or later). Of note, the β2,2-amino acid derivatives
possess a considerably lower amount of positive charges (+2) compared to the intracellular
expressed probes (+5) used by Yeung et al. [39]. This charge difference might be a possible
explanation for the considerable drop in activity of A1 and A2 after 6 h. Thus, the impact of
cationic charge on anti-chlamydial potency of future derivatives must be thoroughly evaluated
since increasing the net positive charge might as well adversely affect the membrane penetrat-
ing properties of the β2,2-amino acid derivatives. These data further suggest a dual mechanism
of action involving both destabilization of EBs and inclusion membranes. The results also indi-
cate that A1 and A2 are active before C. pneumoniae enters its replication cycle, but further
studies are needed to fully elucidate the detailed anti-chlamydial mechanism of action of these
β2,2-amino acid derivatives.
Conclusion
To our knowledge, the current work represents the first report on AMP-like compounds with
activity against intracellular bacteria. The investigated β2,2-amino acid derivatives are chlamy-
dicidal in nature and inhibit C. pneumoniae at clinical relevant concentrations. Thus, by exhib-
iting improved pharmacokinetic properties compared to many reported AMPs the β2,2-amino
acid derivatives A1 and A2 demonstrate an important principle and are promising lead mole-
cules for further drug development of agents with inhibitory activity against the intracellular
pathogen C. pneumoniae.
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